Grafa News and Videos — Page 433

Amarin (NASDAQ:AMRN) reported new post hoc REDUCE-IT Legacy analysis data showing that patients with high adherence to icosapent ethyl experienced an approximately 29%–30% relative reduction in the primary cardiovascular endpoint compared with placebo.

SuperX AI Technology (NASDAQ:SUPX) announced that subsidiary SuperX Microinference signed a long-term equipment and services supply agreement with Australian compute provider Ezisight for 128 B300 AI server clusters.

Best Buy (NYSE:BBY) announced that its Board of Directors authorized a regular quarterly cash dividend of $0.96 per common share, with payment scheduled for October 8, 2026.

Chagee Holdings (NASDAQ:CHA) reported second-quarter 2026 net revenue of RMB3,414.6 million (US$503.3 million), up 2.5% year over year from RMB3,331.9 million.

Gap (NYSE:GAP) lowered its full-year 2026 net sales growth forecast after Old Navy reported weaker-than-expected second-quarter results, with company revenue declining 2% to $3.65 billion.

United Therapeutics (NASDAQ:UTHR) announced eight presentations at the 2026 European Society of Cardiology and European Respiratory Society congresses covering investigational therapies for pulmonary arterial hypertension and other lung diseases.

iBio (NASDAQ:IBIO) reported fiscal 2026 results as it advanced into clinical-stage development, with its Phase 1 trial of IBIO-600 progressing after 31 of 32 participants were dosed across four cohorts.

Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.

Altria Group (NYSE:MO) appointed Steven W. Presley to its Board of Directors effective August 27, 2026, adding a director with experience in food and beverage operations.

Caleres (NYSE:CAL) announced that its Board of Directors declared a regular quarterly cash dividend of $0.07 per share, payable on September 25, 2026.